At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
In people born with certain genetic mutations or whose tumors have these mutations, the standard treatment for breast cancer with CDK4/6 inhibitors (like palbociclib, ribociclib, or abemaciclib) might not be as effective. However, their tumors may still respond to a different type of drug called PARP inhibitors.
-
DAY301 is a type of drug called an antibody-drug conjugate (ADC). ADCs are substances made up of a monoclonal antibody (special protein) linked to a drug. The antibody binds to specific proteins on certain types of cells, including cancer cells. The linked drug enters these cells and kills them. With ADCs, there is a lower risk of harming normal cells, since they usually do not have the target protein.
-
Researchers are assessing different doses of FT825 alone or with cetuximab to treat people with advanced solid tumors. Their tumors have high levels of the HER2 protein. Altered HER2 proteins can fuel cancer growth. 
-
Researchers want to learn if combining lasofoxifene and abemaciclib works well in people with advanced breast cancer. This treatment will be compared to the usual breast cancer treatment with fulvestrant and abemaciclib. The people in this study have breast cancer that is fueled by estrogen and does not have the HER2 protein. They also have a mutation (change or variant) in the ESR1 gene. Lasofoxifene targets the ESR1 gene mutation.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
This study includes people with these cancers:
- A Phase 1 Study of BBO-10203 in People With Advanced Solid Tumors
Full Title A Phase 1a/1b Study of the PI3Ka:RAS Breaker BBO-10203 in Subjects with Advanced Solid Tumors
Purpose
Researchers want to find the best dose of BBO-10203 to use in people with advanced solid tumors. The people in this study have one of these types of cancer that has spread (metastasized):
- Breast cancer that makes an excess amount of the HER2 protein.
- Breast cancer that is negative for HER2 but is fueled by estrogen and/or progesterone.
- Non-small cell lung cancer (NSCLC) with a mutation (change) in the KRAS gene.
- Colorectal cancer with a KRAS mutation.
BBO-10203 may slow or stop cancer growth by blocking the interaction between two proteins. It is taken orally (by mouth).
Who Can Join
To join this study, there are a few conditions. You must:
- Have one of the cancers listed above that continues to grow despite treatment.
- Have recovered from the serious side effects of prior therapies before taking BBO-10203.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Komal Jhaveri’s office at 646-888-4226.
Protocol
25-038Phase
Phase I (phase 1)Disease Status
Newly Diagnosed & Relapsed/RefractoryInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT06625775ClinicalTrials.gov
-
Researchers want to learn how well zelenectide pevedotin works against advanced breast cancer. The people in this study have breast cancer that has come back, spread, or cannot be surgically removed. Their cancers are hormone receptor positive/HER2-negative or are triple negative. In addition, their tumor cells have an amplification (too many copies) of a gene called Nectin4.
-
In this study, researchers want to find out how different amounts of aerobic training might improve cardiorespiratory fitness in people while they are treated for breast cancer. Cardiorespiratory fitness is important for the health of people receiving treatment for breast cancer. Aerobic exercise stimulates and strengthens the heart and lungs and improves how the body uses oxygen.
-
The standard approach to controlling pain after mastectomy includes intravenous and oral pain-relieving medications. In this study, researchers are determining if adding a long-acting local anesthetic, bupivacaine, into the wound at the end of the operation is more effective at reducing pain than the standard medications alone for women having a mastectomy on one side with no immediate reconstruction afterward.